Table 1 Summary of patient characteristics from the trastuzumab adjuvant trials
Characteristic (%) | BCIRG006 | NSABP/N9831 | HERA | FIN HER |
|---|---|---|---|---|
Median age | 49 | 50 | 49 | 51 |
Age<50 years | 52 | 51 | 51 | 51 |
Diameter primary tumor (%) | ||||
Tumor >= 20 mm | 58 | 59.6 | 48.5 | 64.5 |
Estrogen receptor status (%) | ||||
Positive | 56 | 52.2 | 54.5 | 47 |
Negative | 44 | 47.6 | 45.5 | 53 |
Progesterone receptor status (%) | ||||
Positive | 38 | 40.3 | 48.5 | 34 |
Negative | 62 | 59.3 | 61.5 | 66 |
Node negative disease | 29 | 5.7 | 32 | 16 |
Grade III tumor | NA | 69 | 60 | 65 |
Planed endocrine therapy | 54 | 52 | 46 | - |
Taxane based chemotherapy | 100 | 100 | 26 | 50 |
Quality trials by jadad scale | 4 | 4 | 4 | 4 |